<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Oric Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc</link>
<description>Latest news and press releases for Oric Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/oric-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a71a78dffbe2df10bca9.webp</url>
<title>Oric Pharmaceuticals Inc</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc</link>
</image>
<item>
<title>ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-presents-preclinical-data-to-support-the-potential-of-rinzimetostat-across-prostate-cancer-and-in-emerging-resistance-settings-at-the-2026-american-association-for-cancer-research-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-presents-preclinical-data-to-support-the-potential-of-rinzimetostat-across-prostate-cancer-and-in-emerging-resistance-settings-at-the-2026-american-association-for-cancer-research-aacr-annual-meeting</guid>
<pubDate>Fri, 17 Apr 2026 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the presentation of multiple poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting the potential of rinzimetostat (ORIC-944), a potent and selective allosteric inhibitor of PRC2 to treat pro</description>
</item>
<item>
<title>ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-disease-profile-3</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-disease-profile-3</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone</description>
</item>
<item>
<title>ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-to-report-combination-dose-optimization-data-from-phase-1b-trial-of-rinzimetostat-in-patients-with-mcrpc</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-to-report-combination-dose-optimization-data-from-phase-1b-trial-of-rinzimetostat-in-patients-with-mcrpc</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Company to host a conference call and webcast on Tuesday, March 31, 2026 at 4:30 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 27, 2026 (GLOBE</description>
</item>
<item>
<title>ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-announces-preclinical-rinzimetostat-oric-944-presentations-at-the-2026-american-association-for-cancer-research-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-announces-preclinical-rinzimetostat-oric-944-presentations-at-the-2026-american-association-for-cancer-research-aacr-annual-meeting</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company</description>
</item>
<item>
<title>ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-updates</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-updates</guid>
<pubDate>Mon, 23 Feb 2026 21:05:00 GMT</pubDate>
<description>Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic and intracranial activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3 monotherapy dose Raised $264 million from top-tier healthcare</description>
</item>
<item>
<title>ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oric-pharmaceuticals-reports-inducement-grants-213000047</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oric-pharmaceuticals-reports-inducement-grants-213000047</guid>
<pubDate>Fri, 06 Feb 2026 21:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on February 2, 2026 (the “Grant Date”), ORIC granted a total of 173,800 non-qualified stock options and 28,700 restricted stock units to three new non-executive employees who began their employment with ORIC in January 2026. These inducement</description>
</item>
<item>
<title>ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oric-pharmaceuticals-participate-upcoming-investor-210100146</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oric-pharmaceuticals-participate-upcoming-investor-210100146</guid>
<pubDate>Thu, 05 Feb 2026 21:01:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will be participating in the following investor conferences in February: Guggenheim Emerging Outlook: Biotech Summit – Participating in a fireside chat on Thursday, February 12, 2026, at 10:30 a.m. ET. Management will also be participat</description>
</item>
<item>
<title>ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oric-pharmaceuticals-provides-operational-highlights-133000882</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oric-pharmaceuticals-provides-operational-highlights-133000882</guid>
<pubDate>Mon, 12 Jan 2026 13:30:00 GMT</pubDate>
<description>Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic and intracranial activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3 monotherapy dose Raised $244 million from top-tier healthcare special</description>
</item>
<item>
<title>ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company</description>
</item>
<item>
<title>ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-presents-potential-best-class-profile-enozertinib-robust-0</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-presents-potential-best-class-profile-enozertinib-robust-0</guid>
<pubDate>Fri, 05 Dec 2025 05:00:00 GMT</pubDate>
<description>Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases</description>
</item>
<item>
<title>ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-presents-enozertinib-data-nsclc-patients-her2-exon-20-mutations</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-presents-enozertinib-data-nsclc-patients-her2-exon-20-mutations</guid>
<pubDate>Fri, 05 Dec 2025 05:00:00 GMT</pubDate>
<description>Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate</description>
</item>
<item>
<title>ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-presents-potential-best-class-profile-enozertinib-robust-1</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-presents-potential-best-class-profile-enozertinib-robust-1</guid>
<pubDate>Thu, 04 Dec 2025 05:00:00 GMT</pubDate>
<description>Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases 36%</description>
</item>
<item>
<title>ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations</guid>
<pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
<description>Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE)</description>
</item>
<item>
<title>ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-announces-enozertinib-oric-114-poster-presentation-her2-exon-20</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-announces-enozertinib-oric-114-poster-presentation-her2-exon-20</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 01, 2025 (GLOBE</description>
</item>
<item>
<title>ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-participate-8th-annual-evercore-healthcare-conference-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-participate-8th-annual-evercore-healthcare-conference-2025-11</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company</description>
</item>
<item>
<title>ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class</description>
</item>
<item>
<title>ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-announces-completion-dose-exploration-portion-oric-944-phase-1b</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-announces-completion-dose-exploration-portion-oric-944-phase-1b</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>Efficacy data remain consistent with prior disclosure and continue to demonstrate broad and deep PSA responses, with 55% PSA50 response rate and 20% PSA90</description>
</item>
<item>
<title>ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-announces-publication-cancer-research-discovery-and-development</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-announces-publication-cancer-research-discovery-and-development</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company</description>
</item>
<item>
<title>ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-presented-preclinical-data-eortc-nci-aacr-international</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-presented-preclinical-data-eortc-nci-aacr-international</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company</description>
</item>
<item>
<title>ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer</title>
<link>https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-expands-leadership-team-appointment-kevin-brodbeck-chief</link>
<guid isPermaLink="true">https://6ix.com/company/oric-pharmaceuticals-inc/news/oricr-pharmaceuticals-expands-leadership-team-appointment-kevin-brodbeck-chief</guid>
<pubDate>Mon, 18 Aug 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company</description>
</item>
</channel>
</rss>